Company: SMNR
Filing Date: 2025-07-23
Form Type: S-4/A
Source: 0001193125-25-163401
Chunk: 1091

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: S-4/A
Chunk 1091
---
ur’s Relationship with Scilex

Prior to the Business Combination, Semnur is a majority owned subsidiary of Scilex through Scilex’s direct subsidiaries, Scilex, Inc. and Scilex Bio. Following the closing of the Business Combination, Scilex will continue to beneficially own a significant percentage of Semnur’s outstanding common stock. In connection with the Business Combination, Semnur and Scilex intend to enter into certain agreements that relate to Semnur’s relationship with Scilex prior to the Business Combination or will provide a framework for its ongoing relationship with Scilex.**

<div align='center'>Alt-8</div>

[RESALE PROSPECTUS ALTERNATE PAGE] PLAN OF DISTRIBUTION We are registering the offer and resale from time to time by the Selling Stockholders of up to an aggregate of 201,118,000 shares of New Semnur Common Stock. We will not receive any proceeds from the sale by the Selling Stockholders of the shares offered by them described in this prospectus. The aggregate proceeds to the Selling Stockholders will be the purchase price of the shares less any discounts and commissions borne by the Selling Stockholders. The Selling Stockholders will pay any underwriting discounts and commissions and expenses incurred by the Selling Stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholders in disposing of the shares. We are required to pay all other fees and expenses incident to the registration of the shares to be offered and sold pursuant to this prospectus. The shares of New Semnur Common Stock beneficially owned by the Selling Stockholders covered by this prospectus may be offered and sold from time to time by the Selling Stockholders. The term “Selling Stockholders” includes donees, pledgees, transferees or other successors in interest selling shares received after the date of this prospectus from a Selling Stockholder as a gift, pledge, partnership distribution or other transfer. The Selling Stockholders will act independently of us in making decisions with respect to the timing, manner and size of each sale. Such sales may be made on one or more exchanges or in the over-the-countermarket or otherwise, at prices and under terms then prevailing or at prices related to the then current market price or in negotiated transactions. Each Selling Stockholder reserves the right to accept and, together with its respective agents, to reject, any proposed purchase of shares to be made directly or through agents. The Selling Stockholders and any of